FDA Reviews Zoryve Cream for Eczema in Babies as Young as 3 Months
The FDA accepted Arcutis' application for Zoryve (roflumilast) cream in infants 3 months and up with eczema. A decision is expected in early 2027, with nearly half of infants clearing by week four.
Updated
The takeaway
- The FDA accepted Arcutis Biotherapeutics' application to expand roflumilast cream (Zoryve) approval to infants ages 3 months to under 2 years with mild to moderate eczema.
- In the supporting trial, nearly half of treated infants achieved clear or almost clear skin by week four, and over a third showed meaningful itch relief in the same timeframe.
- The FDA is not expected to issue a decision until early 2027; trial side effects were mostly mild, including stomach upset and cold-like symptoms.
The FDA has accepted Arcutis Biotherapeutics' application to expand approval of roflumilast cream (Zoryve) to infants ages 3 months to under 2 years with mild to moderate eczema, Dermatology Times reports. If approved, the once-daily, nonsteroidal topical would become available to parents of very young children — a group with almost no advanced treatment options — and would extend a therapy already prescribed to older kids and adults.
The application rests on trial data showing rapid results in infants. Nearly half of treated infants achieved clear or almost clear skin by week four. Itch relief came fast as well: more than a third of infants showed meaningful improvement in itching within that same timeframe.
The trial's safety profile mirrored what clinicians already see in older children. Reported side effects skewed mild, consisting mostly of stomach upset or cold-like symptoms.
Why the youngest patients have so few options
Christopher Bunick, MD, PhD, editor-in-chief of Dermatology Times, described the current gap in care for this age group in stark terms.
"Children 3 to 24 months of age have very limited options when it comes to treating their atopic dermatitis with an FDA-approved advanced non-steroidal therapy, regardless of whether that therapy is topical or systemic," Bunick said. "News that roflumilast 0.05% cream is on track at the FDA…for approval in this atopic dermatitis population is evidence that potent PDE4 inhibition is effective, safe and tolerable."
The drug's mechanism targets PDE4, an enzyme pathway involved in inflammation. Roflumilast cream already holds approval for older patients, which gives dermatologists an existing safety record to draw on if the infant indication clears the FDA.
What Arcutis is saying
Frank Watanabe, president and CEO of Arcutis, framed the FDA's acceptance of the application as a step toward filling a treatment void.
"Receiving FDA acceptance of this application is an important milestone toward addressing a significant unmet need for infants living with atopic dermatitis and their families," Watanabe said.
What happens next
The cream is not approved for infants yet. The FDA is not expected to make a decision until early 2027.
Until then, parents managing a baby's eczema can rely on gentle, barrier-supporting skin care while they wait to see whether Zoryve becomes the next nonsteroidal option their pediatric dermatologist can prescribe. For the beauty and dermatology trade, an approval in early 2027 would open a pediatric segment that steroid-free topical brands have so far been unable to reach.
Source: NewBeauty; Source: dermatologytimes.com
Grace Kim
Show full bio
Correspondent covering media and advertising at Eurasian Beauty Journal.
